What are the potential side effects of Syndopa (levodopa/carbidopa) in an adult patient with Parkinson's disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Side Effects of Syndopa (Levodopa/Carbidopa)

Syndopa causes a wide range of side effects, with the most common being dyskinesias (involuntary movements), nausea, and orthostatic hypotension, while long-term use carries significant risk of motor complications including wearing-off phenomena and drug-induced dyskinesias that can develop within 5-6 months of treatment initiation. 1

Most Common Adverse Effects

Motor Complications

  • Dyskinesias (choreiform, dystonic, and other involuntary movements) are the most frequently reported adverse reaction with levodopa/carbidopa therapy 1
  • Motor fluctuations and dyskinesias occur in the majority of patients after 5 years of levodopa therapy 2
  • Dyskinesias can develop as early as 5-6 months with higher doses (600 mg/day showed dyskinesias in clinical trials) 3
  • "On-off" phenomenon (bradykinetic episodes) with unpredictable fluctuations in motor response 1
  • Younger age at Parkinson's disease onset, disease severity, and high levodopa doses increase dyskinesia risk 4

Gastrointestinal Effects

  • Nausea is one of the most common side effects, particularly dose-dependent 1, 3
  • Vomiting, anorexia, and weight loss 5, 1
  • Abdominal pain, dyspepsia, constipation, diarrhea 1
  • Dry mouth and taste alterations 6, 1
  • Dark saliva 1
  • Gastrointestinal bleeding and development of duodenal ulcer 1

Cardiovascular Effects

  • Orthostatic hypotension and other orthostatic effects 1
  • Cardiac irregularities, palpitations 1
  • Syncope 1
  • Hypertension (paradoxically can occur) 1

Neuropsychiatric Side Effects

Psychiatric Manifestations

  • Psychotic episodes including delusions, hallucinations, and paranoid ideation 1
  • Confusion, agitation, disorientation 1
  • Depression with or without suicidal tendencies 1
  • Dementia 1
  • Impulse control disorders: pathological gambling, increased libido including hypersexuality 1
  • Dream abnormalities including nightmares 1
  • Anxiety, nervousness, euphoria 1

Neurological Effects

  • Dizziness, somnolence, insomnia 1, 3
  • Headache, paresthesia 1
  • Convulsions (causal relationship not established) 1
  • Peripheral neuropathy 1

Metabolic and Nutritional Effects

Weight and Metabolic Changes

  • Weight loss is common, especially in women, potentially due to higher levodopa dose per kg body weight 5
  • Reduced muscle glucose uptake 5
  • Increased plasma free fatty acids, glucose, growth hormone, and cortisol 5
  • Hyperhomocysteinemia requiring monitoring of vitamin B status (B6, B12, folate) 5
  • Edema and weight gain can also occur paradoxically 1

Hematologic and Laboratory Abnormalities

  • Agranulocytosis, hemolytic and nonhemolytic anemia 1
  • Thrombocytopenia, leukopenia 1
  • Decreased hemoglobin and hematocrit 1
  • Abnormalities in alkaline phosphatase, SGOT (AST), SGPT (ALT), LDH, bilirubin, BUN 1
  • Positive Coombs test 1

Hypersensitivity Reactions

  • Angioedema, urticaria, pruritus 1
  • Henoch-Schönlein purpura 1
  • Bullous lesions including pemphigus-like reactions 1

Dermatologic Effects

  • Rash, increased sweating 1
  • Dark sweat 1
  • Alopecia 1
  • Flushing 1
  • Malignant melanoma (association controversial) 1, 7

Urogenital Effects

  • Urinary tract infection, urinary frequency 1
  • Dark urine 1
  • Urinary retention or incontinence 1
  • Priapism 1

Critical Clinical Considerations

Dose-Related Effects

  • Higher doses increase risk of dyskinesias and nausea in a dose-dependent manner 3
  • Increasing levodopa doses are associated with increased risk for malnutrition 5
  • Blepharospasm may be an early sign of excess dosage requiring dose reduction 1

Long-Term Complications

  • After 5 years, the majority of patients suffer fluctuations, dyskinesias, toxicity, or loss of efficacy 2
  • Once dyskinesias are established, they are difficult to treat 4
  • Motor complications adversely affect quality of life and increase healthcare costs 4

Important Drug Interactions

  • Carbidopa may decrease the effectiveness of droxidopa in Parkinson's patients with neurogenic orthostatic hypotension 8

References

Guideline

Parkinson's Disease Management with Levodopa, Pramipexole, and Rasagiline

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Taste Alteration with Antiparkinsonian Medications

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Adverse effects in the treatment of Parkinson's disease.

Expert review of neurotherapeutics, 2002

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.